micafungin (Mycamine)
Jump to navigation
Jump to search
Indications
- candida
- treatment of esophageal candidiasis
- prevention of candidiasis in patients undergoing bone marrow transplantation
- intravascular catheter-related infection due to Candidia[2]
Dosage
- IV infusion over 60 minutes
- esophageal candidiasis: 150 mg QD
- prophylaxis for bone marrow transplant recipients: 50 mg QD
50 mg lyophilized powder, single-use, in light-protected vials
reconstitue with 5 mg normal saline or 5% dextrose
do NOT shake (excessive foaming)
stable for 24 hours at room temperative after reconstitution
Pharmacokinetics
No dosage adjustment for elderly or renal impairment
Adverse effects
Drug interactions
- micafungin delays elimination of nifedipine & sirolimus
Laboratory
Mechanism of action
- an echinocandin antifungal agent similar to caspofungin
- inhibits the synthesis of beta (1,3)-D-glucan, an essential cell-wall component in Candida & Aspergillus
More general terms
References
- ↑ Prescriber's Letter 12(5): 2005 New Drug: Micafungin (Mycamine) Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=210509&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 2.0 2.1 Medical Knowledge Self Assessment Program (MKSAP) 17, American College of Physicians, Philadelphia 2015
- ↑ http://www.us.astellas.com